Clinical trial
Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular…
NCT00099216 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00099216 |
|---|---|
| Title | Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia |
| Official title | Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Vascular Dementia |
| Intervention type | Drug |
| Interventions | Rivastigmine |
| Enrollment | 708 |
| Start date | Aug 1, 2001 |
| Primary completion | Nov 1, 2005 |
| Completion | Nov 1, 2005 |
| First posted | Dec 10, 2004 |
| Last update posted | Nov 17, 2011 |
| Countries | Austria, Canada, France, Germany, Italy, Russia, Spain, Switzerland, United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: